Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 5/20 | 0.51 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.46 |
| ▸ | HTR6 | P50406 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19397693 | 1.00 | KAT2B (0.51) | KAT2BKAT2ACHRM2CHRM1HTR6 | |
| SCHEMBL17571120 | 0.90 | KAT2B (0.53) | KAT2BKAT2ACHRM2CHRM1HTR6 | |
| SCHEMBL17571719 | 0.90 | KAT2B (0.53) | KAT2BKAT2ACHRM2CHRM1HTR6 | |
| SCHEMBL19397699 | 0.84 | KAT2B (0.52) | KAT2BKAT2ACHRM2CHRM1HTR6 | |
| SCHEMBL17571117 | 0.84 | KAT2B (0.51) | KAT2BKAT2ACHRM2CHRM1HTR6 | |
| SCHEMBL28162110 | 0.84 | KAT2B (0.51) | KAT2BKAT2ACHRM2CHRM1HTR6 | |
| SCHEMBL19402497 | 0.81 | KAT2B (0.58) | KAT2BKAT2ACHRM2CHRM1HTR6 | |
| SCHEMBL19402496 | 0.81 | KAT2B (0.58) | KAT2BKAT2ACHRM2CHRM1HTR6 | |
| SCHEMBL17571738 | 0.81 | KAT2B (0.49) | KAT2BKAT2ACHRM2CHRM1HTR6 | |
| SCHEMBL28162684 | 0.81 | KAT2B (0.49) | KAT2BKAT2ACHRM2CHRM1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275289-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | HDAC10, HDAC6, HDAC1 | KAT2B 41/4885KAT2A 45/4885CHRM2 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.